Medipharm Labs Valuation
| LABS Stock | CAD 0.07 0.01 7.14% |
Medipharm Labs seems to be overvalued based on Macroaxis valuation methodology. Our model forecasts the value of Medipharm Labs Corp from analyzing the firm fundamentals such as Current Valuation of 14.28 M, return on equity of -0.25, and Profit Margin of (0.35) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Medipharm Labs' valuation include:
Price Book 0.5932 | Enterprise Value 14.3 M | Enterprise Value Ebitda (1.82) | Price Sales 0.7078 | Forward PE 27.4725 |
Overvalued
Today
Please note that Medipharm Labs' price fluctuation is out of control at this time. Calculation of the real value of Medipharm Labs Corp is based on 3 months time horizon. Increasing Medipharm Labs' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Medipharm Labs is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Medipharm Stock. However, Medipharm Labs' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.065 | Real 0.0578 | Hype 0.07 | Naive 0.0652 |
The intrinsic value of Medipharm Labs' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Medipharm Labs' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Medipharm Labs Corp helps investors to forecast how Medipharm stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Medipharm Labs more accurately as focusing exclusively on Medipharm Labs' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Medipharm Labs' intrinsic value based on its ongoing forecasts of Medipharm Labs' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Medipharm Labs' closest peers.
Medipharm Labs Cash |
|
Medipharm Valuation Trend
Knowing Medipharm Labs' actual value is paramount for traders when making sound investment determinations. Using both Medipharm Labs' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Medipharm Labs Total Value Analysis
Medipharm Labs Corp is now estimated to have takeover price of 14.28 M with market capitalization of 26.72 M, debt of 2.29 M, and cash on hands of 24.14 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Medipharm Labs fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
14.28 M | 26.72 M | 2.29 M | 24.14 M |
Medipharm Labs Investor Information
The company has price-to-book ratio of 0.59. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Medipharm Labs Corp has Price/Earnings (P/E) ratio of 172.0. The entity recorded a loss per share of 0.03. The firm had not issued any dividends in recent years. Medipharm Labs had 1:2 split on the 4th of October 2018. Based on the key indicators related to Medipharm Labs' liquidity, profitability, solvency, and operating efficiency, Medipharm Labs Corp is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.Medipharm Labs Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Medipharm Labs has an asset utilization ratio of 51.71 percent. This suggests that the Company is making C$0.52 for each dollar of assets. An increasing asset utilization means that Medipharm Labs Corp is more efficient with each dollar of assets it utilizes for everyday operations.Medipharm Labs Ownership Allocation
Medipharm Labs Corp maintains a total of 411.12 Million outstanding shares. Medipharm Labs Corp secures 4.45 % of its outstanding shares held by insiders and 0.71 % owned by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Medipharm Labs Profitability Analysis
The company reported the revenue of 33.06 M. Net Loss for the year was (13.08 M) with loss before overhead, payroll, taxes, and interest of (13.42 M).About Medipharm Labs Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Medipharm Labs Corp. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Medipharm Labs Corp based exclusively on its fundamental and basic technical indicators. By analyzing Medipharm Labs's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Medipharm Labs's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Medipharm Labs. We calculate exposure to Medipharm Labs's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Medipharm Labs's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 4.2 M | 4.4 M | |
| Pretax Profit Margin | (0.40) | (0.42) | |
| Operating Profit Margin | (0.55) | (0.58) | |
| Net Loss | (0.40) | (0.42) | |
| Gross Profit Margin | 0.18 | 0.19 |
Other Information on Investing in Medipharm Stock
Medipharm Labs financial ratios help investors to determine whether Medipharm Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medipharm with respect to the benefits of owning Medipharm Labs security.